The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models

Melanie T. Cushion 1,2,* and Alan Ashbaugh 1,2

Abstract: Rezafungin is a novel echinocandin in Phase 3 development for prevention of invasive fungal disease caused by Candida spp., Aspergillus spp. and Pneumocystis jirovecii in blood and marrow transplantation patients. For such patients, standard antifungal prophylaxis currently comprises an azole for Candida and Aspergillus plus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia (PCP) despite drug-drug-interactions and intolerability that may limit their use, thus, alternatives are desirable. Rezafungin demonstrates a favorable safety profile and pharmacokinetic properties that allow for once-weekly dosing in addition, to antifungal activity against these predominant pathogens. Herein, the in vivo effects of rezafungin against Pneumocystis murina pneumonia were evaluated in immunosuppressed mouse models of prophylaxis and treatment using microscopy and qPCR assessments. In the prophylaxis model, immunosuppressed mice inoculated with P. murina were administered TMP-SMX (50/250 mg/kg 1×/week or 3×/week), caspofungin (5 mg/kg 3×/week), rezafungin (20 mg/kg, 1×/week or 3×/week; 5 mg/kg, 3×/week) intraperitoneally for 2, 4, 6 and 8 weeks, then immunosuppressed for an additional 6 weeks. Rezafungin administered for 4 weeks prevented P. murina from developing infection after rezafungin was discontinued. In the treatment model, immunosuppressed mice with P. murina pneumonia were treated with rezafungin 20 mg/kg 3×/week intraperitoneally for 2, 4, 6 and 8 weeks. Treatment with rezafungin for 8 weeks resulted in elimination of P. murina. Collectively, these studies showed that rezafungin could both prevent infection and eliminate P. murina from the lungs of mice. These findings support the obligate role of sexual reproduction for survival and growth of Pneumocystis spp. and warrant further investigation for treatment of P. jirovecii pneumonia in humans.

Keywords: PCP; Pneumocystis jirovecii pneumonia (PJP) Pneumocystis; echinocandin; rezafungin; obligate sexual reproduction

1. Introduction

Pneumocystis jirovecii is an important fungal pathogen in immunocompromised patients [1–5]. Formerly classified as a zoontic protozoan, Pneumocystis carinii is the name of the Pneumocystis species known to infect rats, while P. jirovecii is the species infecting humans [6]. P. jirovecii can cause severe pneumonia with a high mortality rate especially if untreated [7–9]. Owing to the change of nomenclature, the pneumonia can be referred to as PJP or PJP (Pneumocystis jirovecii pneumonia) in humans. Patients who are most vulnerable to developing PCP are severely immunocompromised following allogeneic hematopoietic stem cell transplantation or solid organ transplantation, those with hematological malignancies undergoing immunosuppressive chemotherapy, as well as patients with rheumatologic disorders and those with HIV infection (CD4 count < 200 cells/µL) [2–4, 10]. Among patients hospitalized for PCP, the most prevalent host factors were malignancies (46%; 61% of the malignancies were hematologic) and HIV infection (18%) [11].
The current recommendation for first-line prophylaxis against PCP is trimethoprim-sulfamethoxazole (TMP-SMX) and is used in high-risk patients throughout the time of treatment-induced immunosuppression or until the CD4 count increases to above 200 cells/µL [2,3,5,12,13]. Prophylaxis is recommended to continue from engraftment or post-transplant for ≥6 months [3,12]. Prolonged prophylaxis for PCP following solid organ transplantation has been suggested in patients at a higher risk of developing late cases of PCP [1,14–16].

Although the efficacy of TMP-SMX is well established, there are concerns for its safety and tolerability, such as bone marrow suppression, liver toxicity and severe skin reactions [12,13]. In an open-label randomized controlled study, up to 42% of patients receiving TMP-SMX for PCP prophylaxis discontinued therapy due to adverse events [17]. Options for second-line prophylaxis, such as aerosolized pentamidine, dapsone and atovaquone, should be considered only if a patient is intolerant to or experiences a severe adverse event from TMP-SMX. None of these agents have been compared with TMP-SMX as first-line prophylaxis in a randomized controlled trial and considerations with their use include cost, bone marrow toxicity, route and frequency of administration and the need for additional prophylactic coverage [12].

Rezafungin is a novel echinocandin currently, in Phase 3 development for prophylaxis of invasive fungal disease in blood and marrow transplantation (ReSPECT NCT04368559). While rezafungin antifungal activity covers a broad-spectrum of Candida and Aspergillus spp. similar to that of currently approved echinocandins [18–20], it is notable for also demonstrating excellent activity against Pneumocystis species (spp.) comparable to that of TMP-SMX, as observed in biofilms and animal models [21–23]. Rezafungin demonstrates a long half-life (~130 h in humans) and safety profile that, as previously reported, refs. [24,25] support front-loaded, once-weekly dosing. Collectively, these data suggest the potential for a simplified, single-agent antifungal prophylaxis regimen with rezafungin.

The echinocandins are a newer class of antifungal agents and currently approved echinocandins have had mixed responses in patients with PCP [26,27]. The mechanism of action, inhibition of β-1,3-D-glucan (BG) synthesis, could explain the disparate efficacy in patients, as Pneumocystis spp. have two distinct life cycle stages: the trophic forms, which do not express BG and the asci, which contain this polymerized sugar in their cell wall [28]. Pneumocystis spp. have been thought to replicate asexually via binary fission of the trophic forms and sexually through a mating process resulting in asci [29]. Recent reports have questioned whether the asexual mode is always operational and suggest these fungi may rely solely on sexual reproduction to proliferate [30]. In studies of murine PCP, it was shown that asci disappear from the infected mouse lungs after 3 weeks of treatment, while large numbers of non-BG expressing organisms remain, illustrating the differential effect on these life cycle stages [28].

In previous studies with rezafungin in immunosuppressed mouse models of prophylaxis and treatment, we reported the inhibition of growth (but not clearance) of all life cycle stages of P. murina [22,23]. Thus, the objectives of the present study were 2-fold: to identify the precise dose and duration of rezafungin (1) that completely prevented infection in the prophylactic mouse model and (2) that eliminated established infection in the treatment mouse model of PCP.

2. Materials and Methods

These studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals, 8th ed. (National Academies Press, Washington, DC, USA), in AAALAC-accredited laboratories under the supervision of veterinarians. In addition, all procedures were conducted in compliance with the Institutional Animal Care and Use Committee at the Veterans Affairs Medical Center, Cincinnati, OH, USA.

To safeguard against environmental exposure of P. murina and other microbes, mice were housed under barrier conditions with autoclaved food; acidified water (sulfuric acid 1 mL/L) and bedding sterilized in shoebox cages equipped with sterile microfilter lids.
Pathogenic bacteria cannot grow in acidified water (pH between 2.5 and 3.0) and many research institutes and universities, as well as The Jackson Laboratory, use acidified water for their mice [31]. Access was limited to animal care and technical personnel who are required to wear sterile caps, gowns, gloves, and booties while in the animal rooms. The animals are observed daily and those that appear gravely ill or moribund are routinely euthanized by a method approved by the AVMA Panel on Euthanasia.

Test agents were supplied by Cidara Therapeutics, Inc. (San Diego, CA, USA). Sulfamethoxazole/Trimethoprim (TMP-SMX) was supplied by Aurobindo Pharma USA (Dayton, NJ, USA). Caspofungin (CAS) was supplied by Merck & Co (Whitehouse Plains, NJ, USA).

2.1. PCP Prophylaxis Mouse Model

(Refer to Scheme 1, below). C3H/HeN mice (Charles River, Wilmington, MA, USA) weighing 20 g were immunosuppressed by adding dexamethasone (4 mg/L) to acidified drinking water. The mice were infected with P. murina organisms isolated from previously infected mice and stored in liquid nitrogen (Cincinnati VAMC, Cincinnati, OH, USA). Such isolates are tested for microbial contamination and ATP content before use as quality control methods [32]. A dose of $2 \times 10^6/50 \, \mu\text{L}$ was instilled by intranasal inoculation along with the concurrent initiation of prophylactic drug treatments. Inoculation of a set number of organisms provides a consistent infection among the groups of mice. Given the slow growing nature of P. murina, drug administration at the time of inoculation models prophylactic administration. Seven groups of mice received one of the following regimens administered intraperitoneally (IP): corticosteroid as negative control, TMP-SMX (50/250 mg/kg, 1×/week or 3×/week) as positive control dosed at the same times as the other test agents, CAS (5 mg/kg, 3×/week) as comparator echinocandin, or rezafungin (20 mg/kg, 1×/week or 3×/week; 5 mg/kg, 3×/week). The control group included 10 mice and each prophylaxis regimen included 40 mice. Prophylaxis was continued for 2, 4, 6 and 8 weeks (n = 10 for each timepoint). A total of 10 mice per group were needed to detect statistically significant differences between groups. Following discontinuation of treatment, mice were immunosuppressed for an additional 6 weeks, allowing for reactivation of any residual P. murina. Mice were then euthanized by CO$_2$ and the lungs were processed for analysis by homogenization. Dilutions of the lung homogenates were dropped on pre-etched slides (10 µL × 3 drops per slide) stained with Diff-Quik and Cresyl Echt Violet (CEV) and microscopically enumerated (30 Oil Immersion Fields at 1250×) to quantify the nuclei and asci forms of the fungus, respectively [28].

Scheme 1. Prophylaxis Model. The arrows above the boxes represent the length of drug administration. After each treatment period, the mice were kept on immunosuppression for 6 weeks. The boxes indicate the timepoints. “i.s” = immunosuppression.
Of note, CAS 5 mg/kg and rezafungin 20 mg/kg doses were selected for this study because they are considered the human equivalent doses in mice. The AUC/C_{max} of CAS 5 mg/kg in mice exceeds that in human [33,34] and serves as a good comparator to rezafungin if administered using the same 3×/week dosing regimen. The 3×/week frequency of rezafungin was chosen because the half-life is shorter in mice (~25 h) [35] versus humans (~130 h) and this dosing regimen would approximate the AUC achieved in humans while compensating for the shorter half-life in mice.

2.2. PCP Treatment Mouse Model

(Refer to Scheme 2, below) C3H/HeN mice (Charles River) (20 g) were infected with *P. murina* through exposure to seed mice (those with fulminant infection) by rotation into the cages for 2 weeks. Mice were immunosuppressed by adding dexamethasone (4 mg/L) to acidified drinking water. The exposure method is a more natural route of infection and can be used in treatment studies because sentinel mice are checked for the presence of standard moderate infections prior to treatment.

![Scheme 2. PCP Treatment Model.](image)

Sixty mice received the immunosuppressant and after 6 weeks of immunosuppression, 10 of the 20 mice that were to receive no treatment (controls) were sacrificed and evaluated for infection. At the same time, the remaining 40 mice were put on rezafungin at 20 mg/kg IP 3×/week for up to 8 weeks of treatment. After 2 weeks of rezafungin treatment (week 8 time point; 6 weeks of immunosuppression + 2 weeks of treatment), 10 of the immunosuppressed, rezafungin-treated mice and the remaining untreated controls (10 mice) were sacrificed. Infected and untreated mice do not survive past this time point. After 4 weeks of rezafungin treatment (week 10 time point), 10 mice were sacrificed and evaluated for infection and after 6 weeks of treatment (week 12 time point), another 10 mice were evaluated. At the final week 14 time point, the remaining 10 mice had received 8 weeks of the rezafungin regimen and were sacrificed. Mice were euthanized by CO₂ inhalation and the lungs were processed for analysis by homogenization. Lung homogenates were microscopically analyzed for organism burdens as described above.

Further analysis by RT-qPCR used total RNA isolated from the lung homogenates with TRIZOL reagent and transcribed to cDNA to quantify *P. murina* ribosomal RNA gene message levels. RT-qPCR was performed using a previously published TaqMan assay [36].

The threshold cycle for each sample was defined as the point at which fluorescence generated by degradation of the TaqMan probe showed a significant increase above baseline. A standard curve using a dilution series of cDNA made from RNA isolated from
$10^7$ *P. murina* nuclei was generated to convert the threshold cycle data to *P. murina* nuclei. This standard curve was used to estimate the level of infection.

2.3. Statistical Analysis

The following statistical analyses were performed for both models (PCP prophylaxis and treatment models). The nuclei and asci count for each lung were log transformed and analyzed by analysis of covariance to determine statistical significance ($p < 0.05$). Individual groups were compared with the Student–Newman–Keuls *t* test for multiple comparisons. Survival curves were based on the 98-day treatment period (GraphPad Prism v9).

3. Results

3.1. PCP Prophylaxis Mouse Model

Significant reductions in both nuclei and asci burdens at all timepoints were observed in all mice that received rezafungin as prophylaxis compared with negative control (vehicle) mice at week 8 (Figure 1). Following 4 weeks of rezafungin prophylaxis (plus 6 weeks of additional immunosuppression; week 10 timepoint), rezafungin 20 mg/kg ($1 \times /\text{week}$ or $3 \times /\text{week}$) prevented *P. murina* from activating an infection. Further, 6 and 8 weeks of rezafungin prophylaxis (week 12 and 14 timepoints) prevented reactivation of *P. murina* in 100% of the mice. Significant differences in nuclei and asci counts between each group given rezafungin and caspofungin (CAS; comparator echinocandin control) were observed at 2 and 4 weeks of treatment (week 8 and 10 timepoints, respectively). Rezafungin prophylaxis resulted in significantly lower nuclei and asci counts at 2, 4 and 6 weeks (week 8, 10 and 12 timepoints) compared with TMP-SMX $1 \times /\text{week}$ (positive treatment control). At week 14, improved survival was observed in the rezafungin 20 mg/kg $3 \times /\text{week}$ prophylaxis group compared with CAS after 56 days of treatment (Figure 2).

3.2. PCP Treatment Mouse Model

Significant reductions in nuclei and asci counts were observed after 2 weeks of rezafungin treatment (8-week study duration) compared with the control group (Figure 3). No asci were present at any of the timepoints in the rezafungin-treated mice and significant reductions in nuclei were observed at all timepoints compared with the control group. Significant reductions in nuclei were observed from week 8 to week 10 and from week 10 to week 12, with no nuclei present at week 14. There was no significant difference in survival between the control group and rezafungin groups.

Analysis by quantitative reverse transcription PCR (RT-qPCR) showed significant reductions of signals at all timepoints in the rezafungin groups compared with the week 8 control group (Figure 4). At the 14-week time point, no signal was detected, indicating elimination of the infection.
Figure 1. Log10 mean nuclei and asci counts after 2 to 8 weeks of prophylactic treatment followed by additional 6 weeks of immunosuppression without treatment. Color code: red = C/S; vehicle treated negative control; green = rezafungin; pink = T/S (trimethoprim/sulfamethoxazole), blue = CAS (caspofungin). Bracket denotes significant difference from week 8 C/S group and CAS group ($p < 0.05$). Capped line indicates significant difference from week 8 C/S group. Red dotted line indicates limit of microscopic detection ($\log_{10} 4.24$).
Figure 2. Survival curves for rezafungin and comparators at Week 14 after 56 treatment days of study. CAS = caspofungin, TMP/SMX = trimethoprim/sulfamethoxazole. * Significant difference between rezafungin 20 mg/kg/3×/week (green line) and CAS (grey line) at week 14 (p < 0.05).

Figure 3. Treatment with rezafungin eliminates P. murina. Log$_{10}$ mean nuclei and asci counts after 2 to 8 weeks of rezafungin treatment. Color code: red = vehicle treated control bars; green = rezafungin-treated 20 mg/kg/3×/week. Bracket denotes significant difference from 8-week control (p < 0.05). # denotes significant difference from previous week timepoint. Red dotted line indicates limit of detection (log$_{10}$ 4.24).

Figure 4. RT-qPCR data from cDNA isolated from lung homogenates and quantified using a TaqMan Assay. Color code: red = vehicle treated control bars; green = rezafungin-treated 20 mg/kg/3×/week. TX = Treatment. Bracket denotes significant difference from 8-week control. # denotes significant difference from previous week timepoint. A 14 week signal is below detection.
4. Discussion

Echinocandins inhibit the synthesis of BG, an essential component of the fungal cell wall [23] found in the asci form of *Pneumocystis* spp. In previous studies using the mouse model of PCP, anidulafungin was shown to halt the sexual cycle of *P. murina* and *P. carinii* by inhibiting the synthesis of BG in the ascus form; however, significant numbers of non-asci forms remained in the lungs [28,37]. Notably, mice without asci due to anidulafungin treatment, were unable to transmit the infection. These studies provided evidence that the ascus is the agent of transmission for *Pneumocystis* spp. and is needed for a productive infection. In addition, echinocandin discontinuation along with continued immunosuppression allowed the asci to repopulate the lungs, showing that those organisms remaining after anidulafungin treatment were viable and able to re activates the infection [28].

In contrast, an early in vivo study evaluating rezafungin as prophylaxis with TMP-SMX as the active control in a mouse model of PCP showed that rezafungin statistically significantly reduced nuclei and asci counts of *P. murina* at all doses tested (20 mg/kg, 1×/week or 3×/week and 5 mg/g/kg 3×/week) and demonstrated in vivo efficacy (20). Furthermore, in the present studies, prophylaxis with rezafungin for as short as 4 weeks prevented *P. murina* organisms from developing an infection after rezafungin had been discontinued and animals were immunosuppressed for an additional 6 weeks, more effectively than CAS.

Data from the treatment mouse model study showed that rezafungin inhibits asci and consequently sexual reproduction in a manner dependent on treatment duration. It can also be surmised that *P. murina* cannot be sustained by alternative means of replication, such as asexual reproduction, in the absence of asci during an extended treatment period with rezafungin.

With the increasing complexity of azole-based prophylaxis (e.g., drug-drug interactions), echinocandins have garnered attention for their potential in antifungal prophylaxis [38,39]. However, despite limited alternatives to standard TMP-SMX, micafungin, anidulafungin and CAS have not been recommended for prophylaxis against PCP based on in vivo efficacy [26,40–42]. The PK profile of rezafungin not only sets it apart from other echinocandins in traditional PK analysis; higher penetration of rezafungin at the infected tissue site, as observed compared with micafungin, may explain observed differences in efficacy compared with other echinocandins [23].

Rezafungin is the first antifungal agent to be studied as a single agent for prophylaxis against *Candida* spp., *Aspergillus* spp. and *P. jirovecii*. Rezafungin has demonstrated in vivo efficacy comparable to that of TMP-SMX and, furthermore, lacks the safety concerns associated with TMP-SMX. While our study was limited to nonclinical models, clinical evaluation of rezafungin to date has demonstrated its safety and efficacy. Rezafungin was safe and well tolerated in single- and multiple-dose studies of intravenous rezafungin administered up to 400 mg once weekly [24,43,44], as well as in the completed Phase 2 trial of rezafungin for treatment of candidemia and invasive candidiasis (STRIVE; NCT02734862) [44]. In the ongoing phase 3, prospective, randomized, double-blind trial of rezafungin for prevention of invasive fungal disease caused by *Candida, Aspergillus* and *P. jirovecii* in patients undergoing allogeneic blood and marrow transplantation (ReSPECT; NCT04368559), the efficacy and safety of once-weekly IV rezafungin will be evaluated compared with standard of care (once-dailyazole plus TMP-SMX).

The in vivo preclinical data reported herein demonstrate the excellent activity of rezafungin against *P. murina* and support its ongoing development as a potential new approach to antifungal prophylaxis and therapy.

**Author Contributions:** Conceptualization, M.T.C. and A.A.; methodology M.T.C. and A.A.; formal analysis, M.T.C. and A.A.; investigation, M.T.C. and A.A.; resources, M.T.C.; data curation, M.T.C. and A.A.; writing—original draft preparation, M.T.C. and A.A.; writing—review and editing, M.T.C. and A.A.; visualization, M.T.C. and A.A.; supervision, M.T.C.; project administration, A.A.; funding acquisition, M.T.C. All authors have read and agreed to the published version of the manuscript.
Funding: These studies were funded by Cidara Therapeutics, Inc., San Diego, CA, USA. Cidara Therapeutics had a role in the design of the study and in the review of this manuscript and its publication; Cidara had no role in the collection, analyses, or interpretation of data. MTC is supported in part by a Biomedical Laboratory Research and Development Senior Research Career Scientist Award from the United States Department of Veterans Affairs (award number IK6BX005232).

Institutional Review Board Statement: These studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals, 8th ed. (National Academies Press, Washington, DC, USA), in AAALAC-accredited laboratories under the supervision of veterinarians. In addition, all procedures were conducted in compliance with the Institutional Animal Care and Use Committee at the Veterans Affairs Medical Center, Cincinnati, OH, USA. Protocol number 20-01-10-01 approved 02/11/2020.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are reported in this study.

Acknowledgments: Editorial assistance was provided by L. O’Brien and T. Chung (Scribant Medical) with funding by Cidara Therapeutics, Inc., San Diego, CA, USA.

Conflicts of Interest: The authors declare no conflict of interest. The published version of this manuscript and final decision to publish was determined solely by the authors.

References

1. Brakemeier, S.; Pfau, A.; Zukunft, B.; Budde, K.; Nickel, P. Prophylaxis and treatment of Pneumocystis jirovecii pneumonia after solid organ transplantation. Pharmacol. Res. 2018, 134, 61–67. [CrossRef] [PubMed]

2. Cordonnier, C.; Cesaro, S.; Maschmeyer, G.; Einsele, H.; Donnelly, J.P.; Alainio, A.; Hauser, P.M.; Lagrou, K.; Melchers, W.J.; Helweg-Larsen, J.; et al. Pneumocystis jirovecii pneumonia: Still a concern in patients with haematological malignancies and stem cell transplant recipients. J. Antimicrob. Chemother. 2016, 71, 2379–2385. [PubMed]

3. Fishman, J.A.; Gans, H. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant. 2019, 33, e13587. [CrossRef]

4. Salzer, H.J.F.; Schafer, G.; Hoenigl, M.; Gunther, G.; Hoffmann, C.; Kalsdorf, B.; Alainio, A.; Lange, C. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia. Respiration 2018, 96, 52–65. [CrossRef]

5. Sokulska, M.; Kicia, M.; Wesolowska, M.; Hendrich, A.B. Pneumocystis jirovecii—From a commensal to pathogen: Clinical and diagnostic review. Parasitol. Res. 2015, 114, 3577–3585. [CrossRef] [PubMed]

6. Redhead, S.A.; Cushion, M.T.; Frenkel, J.K.; Stringer, J.R. Pneumocystis and Trypanosoma cruzi: Nomenclature and typifications. J. Eukaryot. Microbiol. 2006, 53, 2–11. [CrossRef] [PubMed]

7. Truong, J.; Ashurst, J.V. Pneumocystis jirovecii Pneumonia; StatPearls: Treasure Island, FL, USA, 2021.

8. Delliere, S.; Gits-Muselli, M.; Bretagne, S.; Alainio, A. Outbreak-Causing Fungi: Pneumocystis jirovecii. Mycopathologia 2020, 185, 783–800. [CrossRef] [PubMed]

9. Cilloniz, C.; Dominedo, C.; Alvarez-Martinez, M.J.; Moreno, A.; Garcia, F.; Torres, A.; Miro, J.M. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. Expert Rev. Anti. Infect. Ther. 2019, 17, 787–801. [CrossRef] [PubMed]

10. Tabanor, J.A.; Lakshminarayanan, S. Do patients on biologic drugs for rheumatic disease need PCP prophylaxis? Cleve. Clin. J. Med. 2019, 86, 449–453. [CrossRef]

11. Kanj, A.; Samhouri, B.; Abdallah, N.; Chehab, O.; Baqir, M. Host Factors and Outcomes in Hospitalizations for Pneumocystis jirovecii Pneumonia in the United States. Mayo Clin. Proc. 2021, 96, 400–407. [CrossRef]

12. Maertens, J.; Cesaro, S.; Maschmeyer, G.; Einsele, H.; Donnelly, J.P.; Alainio, A.; Hauser, P.M.; Lagrou, K.; Melchers, W.J.; Helweg-Larsen, J.; et al. ECIL guidelines for preventing Pneumocystis jiroveci pneumonia in patients with haematological malignancies and stem cell transplant recipients. J. Antimicrob. Chemother. 2016, 71, 2397–2404. [PubMed]

13. Redjoul, R.; Robin, C.; Foulet, F.; Leclerc, M.; Beckerich, F.; Cabanne, L.; di Blasi, R.; Pautas, C.; Toma, A.; Botterel, F.; et al. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: Can we always follow the guidelines? Bone Marrow Transpl. 2019, 54, 1082–1088. [CrossRef] [PubMed]

14. Choi, Y.I.; Hwang, S.; Park, G.C.; Namgoong, J.M.; Jung, D.H.; Song, G.W.; Ha, T.Y.; Moon, D.B.; Kim, K.H.; Ahn, C.S.; et al. Clinical outcomes of Pneumocystis carinii pneumonia in adult liver transplant recipients. Transplant. Proc. 2013, 45, 3057–3060. [CrossRef] [PubMed]

15. Iriart, X.; Belval, T.C.; Fillaux, J.; Esposito, L.; Lavergne, R.A.; Cardeau-Desangles, I.; Roques, O.; del Bello, A.; Cointault, O.; Lavayssiere, L.; et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am. J. Transpl. 2015, 15, 190–199. [CrossRef] [PubMed]
40. Wang, M.; Lang, G.; Chen, Y.; Hu, C.; Guo, Y.; Tao, R.; Dong, X.; Zhu, B. A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia. *J. Immunol. Res.* 2019, 2019, 8105075. [CrossRef] [PubMed]

41. Zhang, G.; Chen, M.; Zhang, S.; Zhou, H.; Ji, X.; Cai, J.; Lou, T.; Cui, W.; Zhang, N. Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. *Exp. Med.* 2018, 15, 1594–1601. [CrossRef] [PubMed]

42. Tian, Q.; Si, J.; Jiang, F.; Xu, R.; Wei, B.; Huang, B.; Li, Q.; Jiang, Z.; Zhao, T. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection. *HIV Med.* 2021, 22, 307–313. [CrossRef] [PubMed]

43. Sandison, T.; Ong, V.; Lee, J.; Thye, D. Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. *Antimicrob. Agents Chemother.* 2017, 61, e01627-16. [CrossRef] [PubMed]

44. Thompson, G.R.; Soriano, A.; Skoutelis, A.; Vazquez, J.A.; Honore, P.M.; Horcajada, J.P.; Spapen, H.; Bassetti, M.; Ostrosky-Zeichner, L.; Das, A.F.; et al. Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis—The STRIVE Trial. In *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*; The Infectious Diseases Society of America: Arlington, VA, USA, 2020.